000307552 001__ 307552
000307552 005__ 20260108120350.0
000307552 0247_ $$2doi$$a10.1182/blood.2025030722
000307552 0247_ $$2pmid$$apmid:41490515
000307552 0247_ $$2ISSN$$a0006-4971
000307552 0247_ $$2ISSN$$a1528-0020
000307552 037__ $$aDKFZ-2026-00049
000307552 041__ $$aEnglish
000307552 082__ $$a610
000307552 1001_ $$00000-0003-2116-5536$$aDöhner, Hartmut$$b0
000307552 245__ $$aPhase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
000307552 260__ $$aWashington, DC$$bAmerican Society of Hematology$$c2026
000307552 3367_ $$2DRIVER$$aarticle
000307552 3367_ $$2DataCite$$aOutput Types/Journal article
000307552 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767796171_3267578
000307552 3367_ $$2BibTeX$$aARTICLE
000307552 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307552 3367_ $$00$$2EndNote$$aJournal Article
000307552 500__ $$aepub
000307552 520__ $$aCore-binding factor acute myeloid leukemia (CBF-AML) is associated with KIT mutations and deregulated expression of KIT.We report results from the randomized, open-label, phase 3 trial of intensive chemotherapy with or without the multi-kinase inhibitor dasatinib in adult patients with CBF-AML.Patients received '3+7' induction therapy, followed by 4 cycles of high-dose cytarabine; in the investigational arm, patients received dasatinib 100 mg QD on days 8-21 in induction, and on days 6-28 in consolidation cycles, followed by 12-month single-agent dasatinib 100 mg QD. Primary endpoint was event-free survival (EFS). Secondary endpoints included overall survival, relapse-free survival, and cumulative incidence of relapse.202 patients were randomly assigned to the standard arm (n=102) and to the dasatinib arm (n=100). Median age was 49 years (range, 18, 77); 94 patients had t(8;21), 108 had inv(16)/t(16;16); 58 (28.7%) patients had a KIT co-mutation. There was no statistically significant difference in EFS (HR 0.92, 95%-CI 0.63, 1.33; p=0.66) or secondary endpoints between treatment arms. There was also no significant difference in EFS in subgroup analyses according to age, CBF-AML type, and KIT mutation status. The incidence of serious adverse events was higher in the investigational arm (64%) than in the standard arm (36%).In patients with CBF-AML, the addition of dasatinib to intensive chemotherapy failed to improve survival outcomes. The addition of dasatinib was associated with an increase in toxicity. This trial was registered at www.gov as NCT02013648.
000307552 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000307552 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307552 7001_ $$aSpäth, Daniela$$b1
000307552 7001_ $$0P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74$$aSaadati, Maral$$b2$$udkfz
000307552 7001_ $$aFiedler, Walter$$b3
000307552 7001_ $$00000-0002-6276-8002$$aGötze, Katharina S$$b4
000307552 7001_ $$aKoller, Elisabeth$$b5
000307552 7001_ $$aWestermann, Jörg$$b6
000307552 7001_ $$aVogel, Wichard$$b7
000307552 7001_ $$aHeuser, Michael$$b8
000307552 7001_ $$aLübbert, Michael$$b9
000307552 7001_ $$aTischler, Hans-Joachim$$b10
000307552 7001_ $$aGerming, Ulrich$$b11
000307552 7001_ $$00000-0001-9489-7282$$aTeichmann, Lino Lars$$b12
000307552 7001_ $$00000-0002-3658-0284$$aFransecky, Lars$$b13
000307552 7001_ $$00000-0002-3112-9857$$aWölfler, Albert$$b14
000307552 7001_ $$aNachbaur, David$$b15
000307552 7001_ $$aHertenstein, Bernd$$b16
000307552 7001_ $$00000-0003-2744-5491$$aSchroers, Roland$$b17
000307552 7001_ $$00000-0001-7999-4359$$aMartens, Uwe M$$b18
000307552 7001_ $$avon Harsdorf, Stephanie$$b19
000307552 7001_ $$aRadsak, Markus P$$b20
000307552 7001_ $$aAschauer, Gregor$$b21
000307552 7001_ $$aWeißhaar, Stefanie$$b22
000307552 7001_ $$aCorbacioglu, Andrea$$b23
000307552 7001_ $$aSchrade, Anika$$b24
000307552 7001_ $$aGaidzik, Verena I$$b25
000307552 7001_ $$aThol, Felicitas R$$b26
000307552 7001_ $$aPaschka, Peter$$b27
000307552 7001_ $$aBullinger, Lars$$b28
000307552 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b29$$udkfz
000307552 7001_ $$aDöhner, Konstanze$$b30
000307552 7001_ $$00000-0003-3510-4304$$aGanser, Arnold$$b31
000307552 773__ $$0PERI:(DE-600)1468538-3$$a10.1182/blood.2025030722$$gp. blood.2025030722$$pnn$$tBlood$$vnn$$x0006-4971$$y2026
000307552 909CO $$ooai:inrepo02.dkfz.de:307552$$pVDB
000307552 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)609d3f1c1420bf59b2332eeab889cb74$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000307552 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b29$$kDKFZ
000307552 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000307552 9141_ $$y2026
000307552 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD : 2022$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-30
000307552 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bBLOOD : 2022$$d2024-12-30
000307552 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000307552 980__ $$ajournal
000307552 980__ $$aVDB
000307552 980__ $$aI:(DE-He78)C060-20160331
000307552 980__ $$aUNRESTRICTED